Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG0352

NEU3 Knockout HeLa Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Uterus (cervix)

  • Disease:

    Adenocarcinoma

  • Gene Species:

    Homo sapiens (Human)

The NEU3 Knockout HeLa Cell Line is a CRISPR/Cas9-edited HeLa cell model with targeted disruption of the NEU3 gene, eliminating the plasma membrane sialidase that modulates ganglioside composition. It enables investigation of NEU3??s role in EGFR signaling, cell adhesion, and apoptosis, relevant to cervical and colorectal cancer research. Key features include abrogation of ganglioside GM3, GD1a, and GD1b hydrolysis, altering downstream ERK1/2 and AKT pathways. Applicable for ganglioside profiling, migration assays, and drug resistance studies using western blotting, LC-MS, and flow cytometry.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HeLa

    Morphology

    Epithelial-like

    Age

    31 years

    Sex of Donor

    Female

    Gene Name

    NEU3

    Gene Species

    Homo sapiens (Human)

    Gene Identifier

    NCBI Gene ID 10825

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The NEU3 Knockout HeLa Cell Line is a CRISPR/Cas9-edited knockout cell line derived from HeLa cells, with targeted disruption of the NEU3 gene. This loss-of-function model enables dissection of NEU3-dependent ganglioside modulation in a human epithelial cancer background. By eliminating NEU3 sialidase activity, the line facilitates investigation of cell surface glycosylation impacts on signaling and disease.

HeLa cells are a human cervical adenocarcinoma epithelial cell line, HPV18-positive and hypertriploid, serving as a classic cervical cancer model. Their adherent epithelial morphology and rapid growth make them ideal for oncology research. The NEU3 knockout derivative provides a genetically modified comparator for studying glycosylation-driven phenotypes in a well-characterized cancer context.

NEU3 encodes a plasma membrane sialidase that hydrolyzes sialic acids from gangliosides GM3, GD1a, and GD1b, thereby remodeling lipid rafts and modulating EGFR activation. NEU3 is regulated by EGF/EGFR, PKC, MEK/ERK, and SP1, and induced by PMA. Downstream, it enhances phosphorylation of EGFR, ERK1/2, AKT, and FAK, and influences Bcl-2-mediated apoptosis. NEU3 interacts with caveolin-1 and integrin ??1, linking ganglioside metabolism to adhesion and growth factor signaling.

In HeLa cells, NEU3 knockout disrupts ganglioside balance, altering EGFR and integrin signaling, which affects proliferation, migration, and survival. This line is particularly relevant for cervical cancer research, enabling studies on how NEU3-mediated ganglioside remodeling contributes to tumor progression and drug resistance. It also facilitates exploration of cross-talk between ganglioside metabolism and insulin signaling, given HeLa??s use in metabolic studies. The knockout model supports rigorous comparison with parental controls to elucidate NEU3??s role in cancer cell biology.

Researchers can utilize this cell line for western blotting and RT-qPCR to confirm knockout and pathway readouts, ganglioside TLC/LC-MS for glycolipid profiling, and flow cytometry for surface ganglioside detection. Functional assays include proliferation, migration/invasion, EGFR phosphorylation, and apoptosis analyses. Co-immunoprecipitation can probe NEU3 interactions with caveolin-1 or integrin ??1. Applications encompass studies of EGFR signaling, drug resistance, and ganglioside-mediated apoptosis in cervical and colorectal cancer models. For inquiries, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)